H&R GmbH & Co. KGaA Reports Decline in 2025 Nine-Month Results

H&R GmbH & Co. KGaA released preliminary figures for the first nine months of 2025, indicating a slowdown in sales revenue and earnings. The company's EBITDA fell to EUR 60.5 million, representing an 8% decrease from the previous year. Quarterly EBITDA was EUR 20.3 million, down from EUR 24.8 million last year. The EBIT was reported at EUR 5.5 million compared to EUR 9.0 million in 2024, reflecting a broader downtrend in earnings.

Consolidated net income was negative at EUR -0.7 million for the third quarter. Sales revenue also dropped by 8.1% to EUR 310.6 million. Economic conditions and decreased demand impacted business volumes across all segments. The ChemPharm REFINING segment showed improved performance over nine months, but third-quarter results were weaker compared to last year. The ChemPharm SALES and PLASTICS segments recorded lower earnings.

The company anticipates meeting the lower range of its reduced EBITDA forecast of EUR 77.0 million for the year. Official financial figures will be available on November 14, 2025.